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ess: mcazzola@qubisoftSummary In 20 COPD patients (FEV1p65% predicted, ICo80% predicted), we
evaluated changes in the degree of pulmonary hyperinflation after acute adminis-
tration of tiotropium 18mg or budesonide/formoterol 320=9mg. The study consisted
of a screening visit and two study days separated by at least one week. Functional
parameters were measured before and 30, and 120min after inhalation of single
study drug. Both tiotropium and budesonide/formoterol induced significant changes
in functional parameters after 30 and 120min. However, the impact of tiotropium on
the degree of pulmonary hyperinflation was larger than that of budesonide/
formoterol, although only differences in IC and TGV between the two treatments
were significant ðPo0:05Þ, at least after 120min, whereas those in RV were not
significant. The documentation that tiotropium is able to modify IC even after an
acute administration indicates its capacity of influencing expiratory flow limitation
in a very fast manner and this is an important finding. In fact, changes in IC after
bronchodilators in patients with COPD with expiratory flow limitation at rest may
represent an objective tool for prescribing these drugs to attain symptomatic
improvement and better quality of life, even in the absence of a significant increase
in FEV1.
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Bronchodilator medications are central to the
symptomatic management of COPD.1 Long-acting
inhaled bronchodilators are more effective and
convenient. The choice of the specific agent
depends on the availability of medication and the
patient’s response. The combination of a long-
acting b-agonist and an inhaled corticosteroid
should be used for those patients with FEV1o50%
who have significant symptoms despite regular
therapy with long-acting bronchodilators. However,
Tashkin and Cooper,2 after having emphasized the
advantage of tiotropium, a new long-acting antic-
holinergic bronchodilator, on long-acting b2-ago-
nists, have recently suggested to use an inhaled
corticosteroid only in those patients with a forced
expiratory volume in 1 s ðFEV1Þo30%, or frequent
exacerbations.
Since, to our best knowledge, no study has
explored and compared the acute effects of
tiotropium versus a combination therapy with
single inhaler budesonide/formoterol on the de-
gree of pulmonary hyperinflation, the aim of this
study was to investigate the acute effects of these
drugs on pulmonary hyperinflation at rest in
patients with stable COPD. This is a useful
information because assessment of the changes in
inspiratory capacity (IC) after bronchodilators in
patients with COPD with expiratory flow limitation
at rest may represent an objective tool forTable 1 Characteristics of the studied patients.
Patient Sex Age FEV1 FVC
(yrs) (% predicted) (% pred
1 M 61 58 68
2 M 79 47 53
3 M 69 59 64
4 M 61 45 52
5 M 70 50 59
6 M 61 41 49
7 M 70 38 50
8 M 81 45 55
9 M 73 51 58
10 M 75 53 57
11 M 64 43 54
12 M 78 36 47
13 M 71 32 37
14 M 75 45 53
15 M 69 60 64
16 M 73 56 64
17 M 62 27 30
18 M 69 43 51
19 M 70 37 44
20 M 78 46 52prescribing these drugs to attain symptomatic
improvement and better quality of life, even in
the absence of a significant increase in FEV1.
3Patients and methods
Subjects
Twenty consecutive outpatients (14 males) with
stable COPD were enrolled. Inclusion criteria were:
445 yrs of age, current or former smoker (410
pack-yrs) and a diagnosis of COPD as defined by the
American Thoracic Society (ATS)/European Respira-
tory Society position paper,4 an FEV1=FVC ratio of
o70%, and a baseline severity of breathlessness of
at least grade 1 (short of breath when hurrying on a
level or walking up a slight hill) according to
the modified Medical Research Council (MRC)
dyspnoea scale.5 Exclusion criteria included:
unstable respiratory status within the previous four
weeks, a known history of asthma or chronic
respiratory disease other than COPD, any clinically
significant concurrent disease, and a change in
medication for COPD within the four weeks prior to
the screening visit. Patients’ characteristics
and lung function data are given in Table 1.
Each patient gave informed consent and the
study protocol was approved by the local ethics
committee.IC Reversibility 15min after
icted) (% predicted) salbutamol 200mgð%Þ
60 8
49 14
62 18
47 11
55 13
46 22
43 9
49 19
54 20
56 7
49 9
43 4
33 15
48 18
62 13
59 6
29 5
48 13
40 6
48 16
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Figure 1 Changes ðmean semÞ in FEV1 over 120min
following inhalation of tiotropium 18-mg (Tio) or budeso-
nide/formoterol 320=9mg (Bud/Form). Po0:0001 ver-
sus baseline.
1.6
1.9
2.2
2.5
Tio
Bud/Form
**
***  #
***
***
L
Comparison of the acute effect of tiotropium versus a combination therapy 1279Methods
A cross-over, randomized, double-blind study was
carried out. On two separate days (within a span of
7–10 days between each study day), patients
underwent pulmonary function testing and dys-
pnoea evaluation, under basal conditions and after
bronchodilator administration. Standard drug do-
sages were used: two budesonide/formoterol
160=4:5mg inhalations via Turbuhaler + one placebo
inhalation via Handihaler, and two placebo inhala-
tions via Turbuhaler + one tiotropium ð18 mgÞ
inhalation via Handihaler.
In the basal condition and 30 and 120min after
bronchodilator administration, FEV1, IC, and forced
vital capacity (FVC) were assessed. The patients
were investigated in the morning in a sitting
position. IC was determined by a slow manoeuvre
(slow inspiration until maximum volume after
regular tidal breathing), while functional residual
capacity (FRC) was determined by asking patients
to pant at a frequency of 51 Hz against a closed
shutter. This manoeuvre was followed by a slow
manoeuvre to obtain total lung capacity (TLC) and
residual volume (RV). Airway resistance (Raw) and
thoracic gas volume (TGV) were measured using a
constant-volume variable pressure body plethysmo-
graph at each visit according to the methods
described by Coates et al.6 Diffusing capacity of
the lung for carbon monoxide ðDLCOÞ was deter-
mined by the single-breath technique according to
Cotes.7 An apnoea of 10 s was used. Alveolar
volume ðVAÞ was measured, and the quotient
DLCO=VA or Krough index ðKCOÞ was calculated.
These measurements were collected at the same
time intervals as the spirometric assessments.
Statistical analysis
This was a pilot study. Therefore, we did not
calculate the sample size. Analysis of variance was
used for repeated measures and t-test with
Bonferroni correction for multiple comparisons.
The effect of different drugs on giving significant
bronchodilation in terms of changes in FEV1, IC,
FVC, TGV and KCO and was compared by means of
the Chi-squared test for categorical variables with
Yates’ correction. A P value of o0:05 was con-
sidered significant.0 30 60 90 120
min
Figure 2 Changes ðmean semÞ in IC over 120min
following inhalation of tiotropium 18-mg (Tio) or budeso-
nide/formoterol 320=9mg (Bud/Form). Po0:01 and
Po0:001 versus baseline; #Po0:05 between the two
treatments.Results
Both tiotropium and budesonide/formoterol in-
duced significant changes from baseline values infunctional parameters after 30 and 120min (with
the exception of the modification of FVC at 30min
after the inhalation of budesonide/formoterol that
was not statistically significant). FEV1 changes are
illustrated in Fig. 1, whereas Figs. 2 and 3 show
changes in IC and FVC, respectively. The time
course over 2 h of TGV is shown in Fig. 4, whereas
Fig. 5 illustrates the impact of the two treatments
on KCO. Tiotropium was able to modify TGV in a
significant manner at both 30 and 120min, but the
effect of budesonide/formoterol was significant
only at 120min. Both treatments were unable to
modify KCO in a significant manner.
The differences in FEV1 between the tiotropium
and budesonide/formoterol groups were always
nonsignificant ðP40:05Þ. Also the differences in
FVC between the tiotropium and budesonide/
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Figure 3 Changes ðmean semÞ in FVC over 120min
following inhalation of tiotropium 18-mg (Tio) or budeso-
nide/formoterol 320=9mg (Bud/Form). Po0:01 versus
baseline.
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Figure 4 Changes ðmean semÞ in TGV over 120min
following inhalation of tiotropium 18-mg (Tio) or budeso-
nide/formoterol 320=9mg (Bud/Form). Po0:01 and
Po0:001 versus baseline; #Po0:05 between the two
treatments.
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Figure 5 Changes ðmean semÞ in KCO over 120min
following inhalation of tiotropium 18-mg (Tio) or budeso-
nide/formoterol 320=9mg (Bud/Form).
P. Santus et al.1280formoterol groups were always nonsignificant
ðP40:05Þ, whereas that in IC at 120min was
significant ðPo0:05Þ. The differences in TGV were
always significant ðPo0:05Þ whereas those in KCO
were always nonsignificant ðP40:05Þ.Discussion
Our data, together with those of others, suggest
that significant changes in IC and hence pulmonary
hyperinflation occur after both b-agonists and
anticholinergic drugs in COPD patients.8–10 As
expected, both tiotropium and budesonide/formo-
terol combination significantly improved spirome-
try and influenced the degree of pulmonary
hyperinflation, even after their single dose inhala-
tion. However, the impact of tiotropium on the
degree of pulmonary hyperinflation was higher than
that of budesonide/formoterol.
This finding was really unexpected for some
important reasons. We know that FEV1 steady state
with tiotropium is reached within 48 h, while
continued improvements in FVC can be expected
over or beyond the first week of therapy,11 and this
indicates that tiotropium is not a fast-acting agent,
but needs for repeated administrations before
inducing its full activity. On the contrary, there is
documentation that formoterol is able to induce a
fast improvement in IC that reaches a plateau
30min after the inhalation.8 In particular, we have
recently provided evidence that the addition of
budesonide to formoterol influences the fast onset
of action of formoterol in patients with COPD, at
least when the two drugs are administered via a
single inhaler12 and, although there is no docu-
mentation that the fast modification in FEV1 can
also influence hyperinflation in a rapid manner, this
seemed to be a likely possibility considering the
documented effect induced by formoterol alone.8
The second important point is that it has been
observed that formoterol induced its peak change
in FEV1 from baseline 2 h after its inhalation,
whereas the peak change in FEV1 after tiotropium
has been observed after 3 h in patients with
COPD.13 In the present study, the changes between
tiotropium and budesonide/formoterol in IC and
TGV were significantly in favour of tiotropium after
2 h. In any case, it seems interesting to highlight
that also O’Donnell et al.14 documented an
immediate reduction of FRC after the first dose of
tiotropium, which indicates that cholinergic
bronchomotor tone contributes in a significant
manner to expiratory flow limitation.
The documentation that tiotropium is able to
modify IC even after an acute administration points
ARTICLE IN PRESS
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limitation in a very fast manner and, in our opinion,
this is an important finding because in stable COPD
patients, there is a high prevalence of expiratory
flow limitation (about 48%), even when taking into
account the severity of airways obstruction in
terms of FEV1.
15 Changes in IC after bronchodilators
in patients with COPD with expiratory flow limita-
tion at rest may represent an objective tool for
prescribing these drugs to attain symptomatic
improvement and better quality of life, even in
the absence of a significant increase in FEV1.
3
It is more difficult to establish whether tiotro-
pium is really more effective than budesonide/
formoterol in reducing lung hyperinflation, also
because the evaluation of the impact of the two
treatments on the degree of pulmonary hyperinfla-
tion after only their acute administration is too
inconsistent for drawing solid conclusions. There-
fore, the real differences in the impact of
tiotropium and budesonide/formoterol combina-
tion on lung hyperinflation will definitely be
determined after a long-term comparison of these
two treatments in hyperinflated patients.References
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